

Waldenstrom's macroglobulinaemia - Pipeline Insight, 2021

<https://marketpublishers.com/r/W50418B31353EN.html>

Date: March 2021

Pages: 120

Price: US\$ 1,500.00 (Single User License)

ID: W50418B31353EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Waldenstrom's macroglobulinaemia – Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Waldenstrom's macroglobulinaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Waldenstrom's macroglobulinaemia Understanding

Waldenstrom's macroglobulinaemia: Overview

Waldenstrom's macroglobulinaemia is a rare type of cancer that begins in the white blood cells. In this the bone marrow produces too many white blood cells that crowd out the normal healthy blood cells. Waldenstrom macroglobulinaemia is considered a type of non-Hodgkin's lymphoma. It's is also sometimes called lymphoplasmacytic lymphoma. Waldenstrom macroglobulinaemia is slow growing and may not cause signs and symptoms for many years. When they occur the symptoms may include: easy bruising, fatigue, weight loss, fever, numbness in hands and feet's, change in vision and shortness of breath. What causes Waldenstrom's macroglobulinaemia is still not

clear. The disease generally begins with one abnormal white blood cell that develops errors (mutations) in its genetic code. The treatment options may include: chemotherapy, Plasma exchange, Targeted Therapy, Biological therapy and Bone marrow transplant.

'Waldenstrom's macroglobulinaemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Waldenstrom's macroglobulinaemia pipeline landscape is provided which includes the disease overview and Waldenstrom's macroglobulinaemia treatment guidelines. The assessment part of the report embraces, in depth Waldenstrom's macroglobulinaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Waldenstrom's macroglobulinaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Waldenstrom's macroglobulinaemia R&D. The therapies under development are focused on novel approaches to treat/improve Waldenstrom's macroglobulinaemia.

Waldenstrom's macroglobulinaemia Emerging Drugs Chapters

This segment of the Waldenstrom's macroglobulinaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Waldenstrom's macroglobulinaemia Emerging Drugs

BGB-3111: BeiGene

Zanubrutinib (BGB-3111) — a small molecule inhibitor of Bruton's tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other

therapies to treat various B cell malignancies. BGB-3111 has been registered for Waldenstrom's macroglobulinaemia in Canada.

ICP-022: Beijing InnoCare Pharma

ICP-022 (Orelabrutinib) is a specific and selective BTK inhibitor for the treatment of tumors and autoimmune diseases and has been supported by a national special project for the development of innovative drugs. Orelabrutinib is currently being investigated globally in broad clinical programs including Phase I, Phase II and registration trials as a monotherapy and in combination therapies. The drug is being evaluated in phase II stage of development for the treatment of Waldenstrom's macroglobulinaemia.

ABT199: Abbvie

ABT-199 (venetoclax), which is a Bcl-2 inhibitor. Bcl-2 is an apoptosis regulator expressed in high levels in leukemia cells, and it is responsible for the prolonged survival of these cells. Venetoclax will block and modulate the activity of Bcl-2. The clinical trials for ABT199 are being evaluated in phase II stage of development for the treatment of Waldenstrom's macroglobulinaemia in collaboration with Dana-Farber Cancer Institute.

Further product details are provided in the report.....

Waldenstrom's macroglobulinaemia: Therapeutic Assessment

This segment of the report provides insights about the different Waldenstrom's macroglobulinaemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Waldenstrom's macroglobulinaemia

There are approx. 20+ key companies which are developing the therapies for Waldenstrom's macroglobulinaemia. The companies which have their Waldenstrom's macroglobulinaemia drug candidates in the most advanced stage, i.e. preregistration include, BeiGene.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical

development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Waldenstrom's macroglobulinaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Bispecific Antibody

Peptides

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Waldenstrom's macroglobulinaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Waldenstrom's macroglobulinaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Waldenstrom's macroglobulinaemia drugs.

Waldenstrom's macroglobulinaemia Report Insights

- Waldenstrom's macroglobulinaemia Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Waldenstrom's macroglobulinaemia Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Waldenstrom's macroglobulinaemia drugs?

How many Waldenstrom's macroglobulinaemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Waldenstrom's macroglobulinaemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Waldenstrom's macroglobulinaemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Waldenstrom's macroglobulinaemia and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Waldenstrom's macroglobulinaemia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Waldenstrom's macroglobulinaemia – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Waldenstrom's macroglobulinaemia companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Waldenstrom's macroglobulinaemia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Preregistration)

Comparative Analysis

BGB-3111: BeiGene

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

ICP-022: Beijing InnoCare Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

LP168: Newave Pharmaceutical Inc

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical Stage Products

Comparative Analysis

Drug Name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Waldenstrom's macroglobulinaemia Key Companies

Waldenstrom's macroglobulinaemia Key Products

Waldenstrom's macroglobulinaemia- Unmet Needs

Waldenstrom's macroglobulinaemia- Market Drivers and Barriers

Waldenstrom's macroglobulinaemia- Future Perspectives and Conclusion

Waldenstrom's macroglobulinaemia Analyst Views

Waldenstrom's macroglobulinaemia Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Waldenstrom's macroglobulinaemia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Waldenstrom's macroglobulinaemia

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Waldenstrom's macroglobulinaemia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/W50418B31353EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W50418B31353EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970